Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.46 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.44 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.42 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.40 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.40 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.40 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.40 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7658 | 0.98 | — | — | |
| Bromide SCHEMBL20984547 | 0.95 | IDO1 (0.55) | IDO1MEN1KMT2AALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL17395631 | 0.93 | IDO1 (0.53) | IDO1MEN1KMT2AALDH1A1KDM4E | |
| Phosphoric Acid SCHEMBL20984949 | 0.86 | CA1 (0.59) | IDO1MEN1KMT2AALDH1A1KDM4E | |
| Sulfuric Acid SCHEMBL20984183 | 0.86 | IDO1 (0.51) | IDO1MEN1KMT2AALDH1A1KDM4E | |
| Oxalic Acid SCHEMBL20984277 | 0.86 | IDO1 (0.51) | IDO1MEN1KMT2AALDH1A1KDM4E | |
| Nitric Acid SCHEMBL20984383 | 0.82 | IDO1 (0.49) | IDO1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL219895 | 0.79 | TDP1 (0.61) | IDO1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL1687027 | 0.77 | RAPGEF4 (0.61) | IDO1MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL790339 | 0.77 | MEN1 (0.52) | IDO1MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 476 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004697-A | Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material | 同济大学 | 2025-05-16 | — | — | CN | claimed |
| CN-113603619-B | Method for preparing aryl sulfonyl fluoride by taking aryl hydrazine hydrochloride as raw material | 上海应用技术大学 | 2023-02-10 | — | — | CN | claimed |
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2021-06-22 | — | — | US | claimed |
| CN-107663161-B | Continuous flow synthesis process of phenylhydrazine salt and substituted phenylhydrazine salt | 上海惠和化德生物科技有限公司 | 2020-04-10 | — | — | CN | claimed |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | SHANGHAI HYBRID-CHEM TECHNOLOGIES (CN) | 2019-05-23 | — | — | US | claimed |
| CN-103396337-A | Preparation method of 3-bromohydrazinobenzene hydrochloride | TIANJIN CHEM REAGENT RES INST | 2013-11-20 | — | — | CN | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12543495-B2 | Composition, organic optoelectronic device and display device | SAMSUNG SDI CO., LTD. (KR) | 2026-02-03 | — | — | US | disclosed |
| EP-4682146-A1 | COMPOSITION INCLUDING NOVEL PYRIDOINDOLE DERIVATIVE COMPOUND AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES | Neurotarge Co., Ltd. (KR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4321514-B1 | COMPOUND HAVING ALK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | CGENETECH SUZHOU CHINA CO LTD (CN) | 2025-12-03 | — | — | EP | disclosed |
| EP-4629980-A1 | ANTIMICROBIAL COMPOUNDS | SRI International (US) | 2025-10-15 | — | — | EP | disclosed |
| CN-120004697-A | Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material | 同济大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-112789740-B | Composition for organic optoelectronic element, and display device | 三星SDI株式会社 | 2025-04-25 | — | — | CN | disclosed |
| EP-0570931-A2 | Styrenic polymer, process for producing same and multi-layer material comprising same | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1993-11-24 | — | — | EP | disclosed |
| US-5086052-A | Antiarthritic, antiallergens, antiinflammatory agents; also for asthma and psoriasis | ABBOTT LABORATORIES (US) | 1992-02-04 | — | — | US | disclosed |
| US-4970210-A | ENZYME INHIBITORS | ABBOTT LABORATORIES (US) | 1990-11-13 | — | — | US | disclosed |
| EP-0299449-A2 | Pyridazinone, triazinone and oxapyridazinone lipoxygenase inhibiting compounds | ABBOTT LABORATORIES (US) | 1989-01-18 | — | — | EP | disclosed |
| US-4299614-A | Novel algicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones | ELI LILLY AND COMPANY (US) | 1981-11-10 | — | — | US | disclosed |
| US-4118574-A | Herbicidal 1,4-diphenyl-3-pyrazolin-5-ones | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4075003-A | Novel herbicidal method utilizing 1,4-diphenyl-3-pyrazolin-5-ones | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040938-B2 | Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts | HPD, TYR, PDK2 | PTGS2 2185/4885GAA 237/4885EGFR 3049/4885 |
| US-20190152896-A1 | Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts | HPD, TYR, PDK2 | PTGS2 2185/4885GAA 237/4885EGFR 3049/4885 |
| US-12543495-B2 | Composition, organic optoelectronic device and display device | NR2E3, OXER1, ACVRL1 | PTGS2 3164/4885GAA 4369/4885EGFR 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.